Healthcare Industry News:  TomoTherapy 

Devices Oncology Distribution

 News Release - December 6, 2007

TomoTherapy Signs Distribution Agreements in Six New Markets

Company Expands its Presence in the Global Radiation Therapy Marketplace

MADISON, Wis.--(HSMN NewsFeed)--TomoTherapy Incorporated (NASDAQ:TTPY ) today announced that it has signed contracts with distributors in Israel, Greece, Poland, Turkey, Russia and the United Arab Emirates to market, sell and service the TomoTherapy® Hi-Art® treatment system. The new distribution agreements extend access to TomoTherapy’s cancer treatment technology to a significant percentage of the global marketplace.

“We are pleased to expand our international presence,” said Paul Baumgart, TomoTherapy’s director of international distribution. “Until today, our sales efforts have primarily focused on North America, Western Europe and Asia. With these new partners in place, we take another step toward bringing a superior radiation therapy solution to cancer centers and their patients throughout the world.”

According to Baumgart, the new distributors have already been in contact with potential customers. He expects that initial orders could be received within the next few months.

Said Baumgart: “Word has spread that TomoTherapySM treatments are the new standard for radiation therapy. Through the first nine months of 2007, 48 percent of our revenue was generated in markets outside the United States. In 2008, we expect to build on this momentum as we look to add even more markets. Targeted regions include Central and South America, Australia, New Zealand, Africa and parts of Eastern Europe.”

The first cancer patient was treated on a clinical TomoTherapy Hi-Art treatment system in July 2003. Since then, more than 150 systems have been installed around the world. The Hi-Art system’s rapid, widespread adoption is attributed to the clinical efficiency, versatility and capabilities made possible by its innovative design.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, manufactures and sells the TomoTherapy® Hi-Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi-Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company completed its initial public offering in May 2007 and its stock is traded on the NASDAQ Global Market under the symbol TTPY. To learn more about TomoTherapy, please visit our Web site at www.TomoTherapy.com.

Forward-Looking Statements

Statements in this release regarding future business plans and expectations, including but not limited to statements using the terms such as “expect” and “could,” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to risks inherent in the expansion into new markets and geographic areas, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of this date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

©2007 TomoTherapy Incorporated. All rights reserved. The following words and logos used herein or in italicized or stylized text are trademarks or registered trademarks of TomoTherapy Incorporated in the United States and other countries: the TomoTherapy logo, TomoTherapy, Hi-Art and CTrue.


Source: TomoTherapy

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.